Skip to main content
Clinical Trials/NCT04910685
NCT04910685
Recruiting
Phase 2

A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis

Blueprint Medicines Corporation101 sites in 13 countries534 target enrollmentNovember 30, 2021
InterventionsPlaceboElenestinib

Overview

Phase
Phase 2
Intervention
Placebo
Conditions
Not specified
Sponsor
Blueprint Medicines Corporation
Enrollment
534
Locations
101
Primary Endpoint
Part 1: Number of participants with Treatment-emergent Adverse Events (TEAEs)
Status
Recruiting
Last Updated
12 days ago

Overview

Brief Summary

This is a randomized, double-blind, placebo-controlled, Phase 2/3 study comparing the efficacy and safety of elenestinib (BLU-263) + symptom directed therapy (SDT) with placebo + SDT in participants with indolent systemic mastocytosis (ISM) whose symptoms are not adequately controlled by SDT. Parts 1 and 2 will enroll participants with ISM. Participants enrolled in Part 2 will roll over onto Part 3 to receive treatment with elenestinib in an open-label fashion following completion of the earlier Part. Part K will enroll participants with ISM who have previously received an approved selective KIT inhibitor. The study also includes pharmacokinetic (PK) groups that will enroll participants with ISM.

Registry
clinicaltrials.gov
Start Date
November 30, 2021
End Date
September 30, 2032
Last Updated
12 days ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • All Participants:
  • Participant must have an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to
  • Part 1 and PK groups:
  • Participant has confirmed diagnosis of ISM, confirmed by Central Pathology Review
  • Participant must have failed to achieve adequate symptom control for 1 or more Baseline symptoms, as determined by the Investigator, with at least 2 of the following symptom-directed therapies administered: H1 blockers, H2 blockers, proton-pump inhibitors, leukotriene inhibitors, cromolyn sodium, corticosteroids, or omalizumab.
  • Participants must have SDT for ISM symptom management stabilized for at least 14 days prior to starting screening procedures.
  • For participants receiving corticosteroids, the dose must be ≤ 20 mg/day prednisone or equivalent, and the dose must be stable for ≥ 14 days.
  • Participant has confirmed diagnosis of ISM, confirmed by Central Pathology Review
  • Participant has confirmed diagnosis of SSM, confirmed by Central Pathology Review of BM biopsy and central review of B- and C-findings by WHO diagnostic criteria.
  • Participant has confirmed diagnosis of ISM, confirmed by Central Pathology Review

Exclusion Criteria

  • Participant has been diagnosed with any of the following WHO systemic mastocytosis (SM) sub-classifications: cutaneous mastocytosis only, SM with an associated hematologic neoplasm of non-MC lineage (SM-AHN), aggressive SM, mast cell leukemia, or mast cell sarcoma.
  • Participant has been diagnosed with another myeloproliferative disorder.
  • Participant has organ damage attributable to SM.
  • Participant has clinically significant, uncontrolled, cardiovascular disease
  • Participant has a QT interval corrected using Fridericia's formula (QTcF) \> \> 470 milliseconds (msec) (for females) or \> 450 msec (for males).
  • Participant has a history of a primary malignancy that has been diagnosed or required therapy within 3 years. The following prior malignancies are not exclusionary: completely resected basal cell and squamous cell skin cancer, curatively treated localized prostate cancer, and completely resected carcinoma in situ of any site.
  • Time since any cytoreductive therapy including masitinib and midostaurin should be at least 5 half-lives or 14 days (whichever is longer), and for cladribine, interferon alpha, pegylated interferon, or antibody therapy \< 28 days or 5 half-lives of the drug (whichever is longer), before beginning the screening period.
  • Participant has received radiotherapy or psoralen and ultraviolet A (PUVA) therapy \< 14 days before beginning the screening period.
  • Other protocol-defined criteria apply.

Arms & Interventions

(Part 2) Placebo + SDT

Participants will receive SDT and matching placebo. SDT will be determined on a per participant basis. Placebo will be administered orally, once daily for approximately 48 weeks.

Intervention: Placebo

(Part 1) Elenestinib Dose 1 + SDT

Participants will receive SDT and elenestinib. SDT will be determined on a per participant basis. Elenestinib will be administered orally, once daily until completion of Part 1.

Intervention: Elenestinib

(Part 1) Placebo + SDT

Participants will receive SDT and matching placebo. SDT will be determined on a per participant basis. Placebo will be administered orally, once daily until completion of Part 1.

Intervention: Placebo

(Part S) Elenestinib Dose 1 + SDT

Participants will receive SDT and elenestinib. SDT will be determined on a per participant basis. Elenestinib will be administered orally, once daily for up to approximately 5 years.

Intervention: Elenestinib

(Part 2) Elenestinib Dose 1 + SDT

Participants will receive SDT and elenestinib. SDT will be determined on a per participant basis. Elenestinib will be administered orally, once daily for approximately 48 weeks.

Intervention: Elenestinib

(Part 3) Elenestinib + SDT

Participants will receive SDT and elenestinib. SDT will be determined on a per participant basis. Elenestinib will be administered orally, once daily for up to approximately 5 years.

Intervention: Elenestinib

(Part 1) Elenestinib Dose 3 + SDT

Participants will receive SDT and elenestinib. SDT will be determined on a per participant basis. Elenestinib will be administered orally, once daily until completion of Part 1.

Intervention: Elenestinib

(Part 1) Elenestinib Dose 2 + SDT

Participants will receive SDT and elenestinib. SDT will be determined on a per participant basis. Elenestinib will be administered orally, once daily until completion of Part 1.

Intervention: Elenestinib

(Part K) Elenestinib Dose 1 + SDT

Participants will receive SDT and elenestinib. SDT will be determined on a per participant basis. Elenestinib will be administered orally, once daily for up to approximately 5 years.

Intervention: Elenestinib

(PK groups) Elenestinib + SDT

Participants will receive SDT and elenestinib. SDT will be determined on a per participant basis. Elenestinib will be administered orally, once daily for up to approximately 5 years.

Intervention: Elenestinib

Outcomes

Primary Outcomes

Part 1: Number of participants with Treatment-emergent Adverse Events (TEAEs)

Time Frame: Up to 12 weeks

Part 1: Mean change from baseline in ISM-Symptom in Assessment Form (ISM-SAF) Total Symptom Score (TSS)

Time Frame: Baseline, Week 13

Part 2: Mean change from baseline in ISM-SAF TSS

Time Frame: Baseline, Week 49

Part 3: Number of participants with Adverse Events (AEs)

Time Frame: Up to 5 years

Part 3: Change from baseline in ISM-SAF TSS

Time Frame: Baseline up to 5 years

Secondary Outcomes

  • Part 1: Change from baseline in serum tryptase(Baseline, Week 13)
  • Part 1: Change from baseline in KIT D816V allele fraction in blood(Baseline, Week 13)
  • Part 1: Change from baseline in Bone Marrow (BM) mast cells(Baseline, Week 13)
  • Part 1: Mean change from baseline in ISM-SAF individual symptom scores(Baseline, Week 13)
  • Part 1: Time to achieve 30% reduction from baseline in ISM-SAF TSS(Baseline up to Week 13)
  • Part 1: Time to achieve 30% reduction from baseline in ISM-SAF domain scores(Baseline up to Week 13)
  • Part 2: Proportion of participants achieving normalized tryptase(Baseline up to Week 49)
  • Part 2: Proportion of participants who achieve an undetectable level or at least a 50% reduction in KIT D816V Variant Allele Frequency (VAF)(Baseline up to Week 49)
  • Part 2: Proportion of participants achieving symptom control as defined by achieving mild symptoms(Baseline up to Week 49)
  • Part 2: Mean percent change from baseline in Bone Mineral Density (BMD)(Baseline, Week 49)
  • Part 2: Mean change from baseline in the annualized rate of anaphylaxis events(Baseline, Weeks 25 to 48)
  • Part 2: Mean change from baseline in Quality of Life (QoL) scores(Baseline, Week 49)
  • Part 2: Mean change from baseline in ISM-SAF domain scores(Baseline, Week 49)
  • Part 2: Number of participants with AEs(Up to Week 49)
  • Part 2: Proportion of participants with a 50% reduction in ISM-SAF TSS(Baseline, Weeks 24 and 48)
  • Part 2: Proportion of participants with a 50% reduction in ISM-SAF domain scores(Baseline, Weeks 24 and 48)
  • Part 2: Proportion of participants with a 30% reduction in ISM-SAF TSS(Baseline, Weeks 24 and 48)
  • Part 2: Proportion of participants with a 30% reduction in ISM-SAF domain scores(Baseline, Weeks 24 and 48)
  • Part 3: Proportion of participants achieving symptom control as defined by achieving mild symptoms(Baseline up to 5 years)
  • Part 3: Change from baseline in ISM-SAF domain scores(Baseline, up to 5 years)
  • Part 3: Proportion of participants achieving a normalized tryptase(Baseline up to 5 years)
  • Part 3: Change from baseline in BMD(Baseline up to 5 years)
  • Part 3: Change from baseline in the annualized rate of anaphylaxis events(Baseline up to 5 years)
  • Parts 2 and 3: Change from baseline in serum tryptase(Baseline up to 5 years)
  • Parts 2 and 3: Change from baseline in KIT D816V allele fraction in blood(Baseline up to 5 years)
  • Parts 2 and 3: Change from baseline in Bone Marrow (BM) mast cells(Baseline up to 5 years)
  • Parts 2 and 3: Proportion of participants achieving controlled disease(Baseline up to 5 years)
  • Parts 2 and 3: Change from baseline in skin lesions as assessed by the fractional body surface area of the most affected skin area(Baseline up to 5 years)
  • Parts 2 and 3: Change from baseline in the number of concomitant medications identified as SDT(Baseline up to 5 years)
  • Parts 2 and 3: Change from baseline in ISM-SAF Individual Symptom Scores(Baseline up to 5 years)
  • Parts 2 and 3: Change from baseline in ISM-SAF Lead (most severe) Symptom Score(Baseline up to 5 years)
  • Parts 2 and 3: Change from baseline in QoL scores(Baseline up to 5 years)
  • Part S: Number of participants with AEs(Baseline up to 5 years)
  • Part S: Proportion of participants who achieve a Pure Pathologic Response (PPR)(Baseline up to 5 years)
  • Part S: Mean change from baseline in ISM-SAF(Baseline, Week 25)
  • Part K: Number of participants with AEs(Baseline up to 5 years)
  • Part K: Change from baseline in serum tryptase(Baseline up to 5 years)
  • Part K: Change from baseline in KIT D816V allele fraction in blood(Baseline up to 5 years)
  • Part K: Mean change from baseline in ISM-SAF TSS(Baseline up to 5 years)
  • Part K: Change from baseline in QoL scores(Baseline up to 5 years)

Study Sites (101)

Loading locations...

Similar Trials

Related News